Cargando…
Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
Pediatric-onset Evans syndrome (pES) is defined by both immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) before the age of 18 years. There have been no comprehensive long-term studies of this rare disease, which can be associated to various immunopathological manifestatio...
Autores principales: | Pincez, Thomas, Fernandes, Helder, Leblanc, Thierry, Michel, Gérard, Barlogis, Vincent, Bertrand, Yves, Neven, Bénédicte, Chahla, Wadih Abou, Pasquet, Marlène, Guitton, Corinne, Marie-Cardine, Aude, Pellier, Isabelle, Armari-Alla, Corinne, Benadiba, Joy, Blouin, Pascale, Jeziorski, Eric, Millot, Frédéric, Paillard, Catherine, Thomas, Caroline, Cheikh, Nathalie, Bayart, Sophie, Fouyssac, Fanny, Piguet, Christophe, Deparis, Marianna, Briandet, Claire, Doré, Eric, Picard, Capucine, Rieux-Laucat, Frédéric, Landman-Parker, Judith, Leverger, Guy, Aladjidi, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804581/ https://www.ncbi.nlm.nih.gov/pubmed/33440924 http://dx.doi.org/10.3324/haematol.2020.271106 |
Ejemplares similares
-
Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort
por: Aladjidi, Nathalie, et al.
Publicado: (2015) -
RASopathies: From germline mutations to somatic and multigenic diseases
por: Riller, Quentin, et al.
Publicado: (2021) -
PD-L1 is expressed on human activated naive effector CD4(+) T cells. Regulation by dendritic cells and regulatory CD4(+) T cells
por: Mazerolles, Fabienne, et al.
Publicado: (2021) -
A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
por: Pasquet, Marlène, et al.
Publicado: (2017) -
Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study
por: Mahlaoui, Nizar, et al.
Publicado: (2023)